—As more men are cured of prostate cancer, or are long-term survivors, the challenges of survivorship are in the spotlight. Improved screening practices, earlier detection, and better therapies have ...

Metformin did not prevent development of metabolic syndrome in men receiving androgen deprivation therapy for prostate cancer in a phase III trial. Metformin was associated with improvement in weight, ...

A partitioned-survival lifetime model (2025 USD) compared ADT alone with seven intensification strategies across PFS, post-progression, and death, using published survival curves and literature-based ...

Short-term androgen deprivation combined with high-dose radiation therapy aids oncologic control in localized prostate cancer. In patients with intermediate- or high-risk localized prostate cancer, ...

The testosterone threshold should be less than 10 ng/dL rather than less than 50 ng/dL for gauging advanced prostate cancer prognosis in patients on ADT. Examining sustained testosterone suppression ...

A meta-analysis explores whether there’s a survival benefit to adding hormone therapy to postoperative radiation for patients with low PSA levels.

(UroToday.com) The 2026 European Association of Urology (EAU) annual meeting featured a plenary prostate cancer session and a ...